AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAY 1 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Vaccine researchers in the United States and Thailand have elucidated the HIV-specific T-cell profile in "highly exposed but persistently seronegative" women (HW).
Nattawan Promadej and colleagues at the Centers for Disease Control and Prevention and Emory University's Vaccine Research Center in Atlanta, Johns Hopkins University in Baltimore, and the Research Institute of Health Science in Chiang Mai, Thailand examined a cohort of HWs and their HIV-infected partners.
Virus-specific T-cell activity was less extensive in HWs compared to their seropositive partners, but was "remarkably" persistent in the absence of HIV exposure, Promadej and coauthors found.
Gamma interferon-based enzyme-linked immunospot assays (ELISAs) were used to evaluate HIV-specific T-cell activity in 18 HWs and their infected male partners. All of the seropositive participants - but only half of the HWs - demonstrated T-cell responses to one or more viral proteins, according to the report.
Almost all (94%) of the seropositive men carried T cells targeting the HIV envelope protein Env, used in many vaccine candidates, study data showed. However, Env-specific T cells were found in only two of the nine persistently seronegative women with ...
Source: HighBeam Research, T-cell responses in persistently seronegative women characterized.